title: Experimental small bowel transplantation using newborn intestine in rats: II. Revascularization of newborn intestine is independent of vascular endothelial growth factor.
abstract: BACKGROUND
  Fetal and newborn intestine often are revascularized after subcutaneous transplantation without surgical vascular anastomosis. However, the mechanism of this ability remains unclear.
  
  
  METHODS
  First, the ability of natural revascularization in newborn organs was tested. Newborn organs in whole (liver, kidney, heart, intestine, spleen, and pancreas) were grafted i nto the subcuta neous tissue of the adult rat and evaluated histopathologically 2 weeks after transplantation. Second, expression of vascular endothelial growth factor (VEGF) mRNA in the intestinal graft was determined before and after transplantation. Finally, we tested whether the free graft survival of newborn intestine was interrupted by TNP-470, an antiangiogenic agent.
  
  
  RESULTS
  Spleen and intestine were revascularized at a higher rate (91.6%, 75%, respectively), and kidney and heart grafts survived at a lower rate (41.7%, 25%, respectively). But all of liver and pancreas grafts failed to be revascularized. VEGF mRNA was not induced in the course of revascularizing. Furthermore, TNP-470 did not interfere with neovascularization of the newborn intestinal graft in vivo.
  
  
  CONCLUSIONS
  Each organ had an organ-specific angiogenic activity. Neovascularization of intestinal graft was not dependent on VEGF expression.
authors.affiliation: Center for Molecular Medicine, Department of Clinical Pharmacology, Jichi Medical School, Tochigi, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Uchida
authors.forename: E
authors.initials: E
authors.lastname: Kobayashi
authors.forename: K
authors.initials: K
authors.lastname: Yanagisawa
authors.forename: K
authors.initials: K
authors.lastname: Mizuta
authors.forename: Y
authors.initials: Y
authors.lastname: Kitoh
authors.forename: A
authors.initials: A
authors.lastname: Fujimura
authors.forename: S
authors.initials: S
authors.lastname: Tominaga
authors.forename: H
authors.initials: H
authors.lastname: Kawarasaki
authors.forename: K
authors.initials: K
authors.lastname: Hashizume
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D003510:Cyclohexanes; D016228:Endothelial Growth Factors / Q000502:physiology*; D007421:Intestine, Small / Q000098:blood supply* / Q000637:transplantation*; D008222:Lymphokines / Q000502:physiology*; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology*; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D020033:Protein Isoforms / Q000502:physiology*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011917:Rats, Inbred Lew; D012717:Sesquiterpenes / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D020533:Angiogenesis Inhibitors; D003510:Cyclohexanes; D016228:Endothelial Growth Factors; D008222:Lymphokines; D020033:Protein Isoforms; D012333:RNA, Messenger; D012717:Sesquiterpenes; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000077609:O-(Chloroacetylcarbamoyl)fumagillol